TOP TEN perturbations for 1029_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1029_s_at
Selected probe(set): 206828_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1029_s_at (206828_at) across 6672 perturbations tested by GENEVESTIGATOR:

CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-4.3946686
Number of Samples:3 / 3
Experimental CAR T cell study 4 (GFP; post-infusion)
CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

dengue fever study 10 (DHF) / normal naive CD8 T cell sample

Relative Expression (log2-ratio):-4.3678627
Number of Samples:2 / 5
Experimental dengue fever study 10 (DHF)
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis.
Control normal naive CD8 T cell sample
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-3.9536552
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-3.384654
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-3.3395834
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

kidney transplantation study 12 (2 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-3.1234608
Number of Samples:6 / 5
Experimental kidney transplantation study 12 (2 week)
CD4+ T-cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

breast cancer study 24 / breast cancer study 22

Relative Expression (log2-ratio):-3.1018143
Number of Samples:10 / 10
Experimental breast cancer study 24
Freshly purified CD4+ tumor-infiltrating T cells derived from female primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion.
Control breast cancer study 22
Freshly purified CD4+ T cells from peripheral blood of female donors with primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information.

gestational age study 1 (term) / elective termination placenta (1st trim.) tissue

Relative Expression (log2-ratio):2.8963623
Number of Samples:4 / 4
Experimental gestational age study 1 (term)
Term human placenta samples obtained from scheduled uncomplicated C-sections.
Control elective termination placenta (1st trim.) tissue
First trimester placenta samples (45-59 days) obtained from uncomplicated elective termination.

breast cancer study 24 / breast cancer study 23

Relative Expression (log2-ratio):-2.8544521
Number of Samples:10 / 10
Experimental breast cancer study 24
Freshly purified CD4+ tumor-infiltrating T cells derived from female primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion.
Control breast cancer study 23
Freshly purified CD4+ T cells from axillary lymph nodes of female donors with primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion.

Langerhans cell histiocytosis study 3 / Langerhans cell histiocytosis study 4

Relative Expression (log2-ratio):-2.8318224
Number of Samples:10 / 7
Experimental Langerhans cell histiocytosis study 3
CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease).
Control Langerhans cell histiocytosis study 4
CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease).